Quantitative multiplex PCR assay for the detection of the seven clinically most relevant high-risk HPV types

Journal of Clinical Virology

Volumn 44, Issue 4, 2009, Pages 302-307

  Schmitz, Martina ^a   Scheungraber, Cornelia ^a   Herrmann, Jörg ^a   Teller, Karin ^a   Gajda, Mieczyslaw ^a   Runnebaum, Ingo B ^a   Dürst, Matthias ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Genotyping; HPV; Multiplex real time PCR; Viral load

Indexed keywords

FLUORESCENT DYE; PLASMID DNA; VIRUS DNA;

ARTICLE; CANCER GROWTH; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DNA DETERMINATION; DNA EXTRACTION; FEMALE; GENOTYPE; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VIRUS CARCINOGENESIS; VIRUS DETECTION; VIRUS LOAD; WART VIRUS;

CERVIX UTERI; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 62749163782     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2009.01.006     Document Type: Article

References (30)

1. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12-19
2. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003) 518-527
3. Munoz N., Castellsague X., de Gonzalez A.B., and Gissmann L. HPV in the etiology of human cancer. Vaccine 24 Suppl. 3 (2006) S3/1-S/10 [Chapter 1]
4. Cuzick J., Clavel C., Petry K.U., Meijer C.J., Hoyer H., Ratnam S., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119 (2006) 1095-1101
5. Grce M., and Davies P. Human papillomavirus testing for primary cervical cancer screening. Expert Rev Mol Diagn 8 (2008) 599-605
6. Wright Jr. T.C., Schiffman M., Solomon D., Cox J.T., Garcia F., Goldie S., et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 103 (2004) 304-309
7. van Ham M.A., Bakkers J.M., Harbers G.K., Quint W.G., Massuger L.F., and Melchers W.J. comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders. J Clin Microbiol 43 (2005) 2662-2667
8. Jacobs M.V., de Roda Husman A.M., van den Brule A.J., Snijders P.J., Meijer C.J., and Walboomers J.M. Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J Clin Microbiol 33 (1995) 901-905
9. Manos M., Ting Y., Wright D., Lewis A., Broker T., and Wolinsky S. Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells 7 (1989) 209-214
10. Castle P.E., Solomon D., Schiffman M., and Wheeler C.M. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 97 (2005) 1066-1071
11. Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97 (2005) 1072-1079
12. Venturoli S., Ambretti S., Cricca M., Leo E., Costa S., Musiani M., et al. Correlation of high-risk human papillomavirus genotypes persistence and risk of residual or recurrent cervical disease after surgical treatment. J Med Virol 80 (2008) 1434-1440
13. Brummer O., Hollwitz B., Bohmer G., Kuhnle H., and Petry K.U. Human papillomavirus-type persistence patterns predict the clinical outcome of cervical intraepithelial neoplasia. Gynecol Oncol 102 (2006) 517-522
14. Kleter B., van Doorn L.J., Schrauwen L., Molijn A., Sastrowijoto S., ter Schegget J., et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 37 (1999) 2508-2517
15. van den Brule A.J., Pol R., Fransen-Daalmeijer N., Schouls L.M., Meijer C.J., and Snijders P.J. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 40 (2002) 779-787
16. Lindh M., Gorander S., Andersson E., Horal P., Mattsby-Balzer I., and Ryd W. Real-time Taqman PCR targeting 14 human papilloma virus types. J Clin Virol 40 (2007) 321-324
17. Nishiwaki M., Yamamoto T., Tone S., Murai T., Ohkawara T., Matsunami T., et al. Genotyping of human papillomaviruses by a novel one-step typing method with multiplex PCR and clinical applications. J Clin Microbiol 46 (2008) 1161-1168
18. Holland P.M., Abramson R.D., Watson R., and Gelfand D.H. Detection of specific polymerase chain reaction product by utilizing the 5′-3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci USA 88 (1991) 7276-7280
19. Munoz N., Bosch F.X., Castellsague X., Diaz M., de Sanjose S., Hammouda D., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111 (2004) 278-285
20. Schiffman M., Khan M.J., Solomon D., Herrero R., Wacholder S., Hildesheim A., et al. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst 97 (2005) 147-150
21. Durst M., Gissmann L., Ikenberg H., and zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 80 (1983) 3812-3815
22. Jacobs M.V., Snijders P.J., van den Brule A.J., Helmerhorst T.J., Meijer C.J., and Walboomers J.M. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 35 (1997) 791-795
23. Jacobs M.V., Snijders P.J., Voorhorst F.J., Dillner J., Forslund O., Johansson B., et al. Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison. J Clin Pathol 52 (1999) 498-503
24. Klug S.J., Hukelmann M., Hollwitz B., Duzenli N., Schopp B., Petry K.U., et al. Prevalence of human papillomavirus types in women screened by cytology in Germany. J Med Virol 79 (2007) 616-625
25. Bulkmans N.W., Rozendaal L., Snijders P.J., Voorhorst F.J., Boeke A.J., Zandwijken G.R., et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44 102 women. Int J Cancer 110 (2004) 94-101
26. Schneider A., Hoyer H., Lotz B., Leistritza S., Kuhne-Heid R., Nindl I., et al. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer 89 (2000) 529-534
27. Sabol I., Salakova M., Smahelova J., Pawlita M., Schmitt M., Gasperov N.M., et al. Evaluation of different techniques for identification of human papillomavirus types of low prevalence. J Clin Microbiol 46 (2008) 1606-1613
28. Yoshida T., Sano T., Kanuma T., Owada N., Sakurai S., Fukuda T., et al. Quantitative real-time polymerase chain reaction analysis of the type distribution, viral load, and physical status of human papillomavirus in liquid-based cytology samples from cervical lesions. Int J Gynecol Cancer 18 (2008) 121-127
29. Fiander A.N., Hart K.W., Hibbitts S.J., Rieck G.C., Tristram A.J., Beukenholdt R.W., et al. Variation in human papillomavirus type-16 viral load within different histological grades of cervical neoplasia. J Med Virol 79 (2007) 1366-1369
30. Monnier-Benoit S., Dalstein V., Riethmuller D., Lalaoui N., Mougin C., and Pretet J.L. Dynamics of HPV16 DNA load reflect the natural history of cervical HPV-associated lesions. J Clin Virol 35 (2006) 270-277